Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trial.

Alexander Röth,Satoshi Ichikawa,Yoshikazu Ito,Jin Seok Kim,Zsolt Nagy,Naoshi Obara,Jens Panse,Hubert Schrezenmeier,Simona Sica,Juliette Soret,Kensuke Usuki,Sung-Soo Yoon,Nadiesh Balachandran,Muriel Buri,Pontus Lundberg, Himika Patel,Kenji Shinomiya,Alexandre Sostelly,Jun-Ichi Nishimura

European journal of haematology（2023）

引用 0|浏览10

暂无评分

摘要

Over a 3-year median treatment duration, crovalimab was well tolerated and sustained C5 inhibition was achieved. Intravascular haemolysis control, haemoglobin stabilisation and transfusion avoidance were maintained, signifying long-term crovalimab efficacy.

查看译文

关键词

paroxysmal nocturnal haemoglobinuria,treatment

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要